John C. Phares

753 total citations
7 papers, 587 citations indexed

About

John C. Phares is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John C. Phares has authored 7 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Genetics and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John C. Phares's work include Cancer therapeutics and mechanisms (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). John C. Phares is often cited by papers focused on Cancer therapeutics and mechanisms (3 papers), Neuroendocrine Tumor Research Advances (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). John C. Phares collaborates with scholars based in United States. John C. Phares's co-authors include Daniel C. Ihde, P L Duffey, Vincent T. DeVita, Dan L. Longo, S M Hubbard, Elaine S. Jaffe, Robert C. Young, Eli Glatstein, Walter J. Urba and Margaret Edison and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Lung Cancer.

In The Last Decade

John C. Phares

7 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John C. Phares United States	6	369	323	201	174	137	7	587
Manuel F. Rosado United States	10	249 0.7×	333 1.0×	63 0.3×	29 0.2×	113 0.8×	14	491
JR Redman United States	6	396 1.1×	618 1.9×	119 0.6×	26 0.1×	215 1.6×	8	720
Olav Erich Yri Norway	10	218 0.6×	202 0.6×	112 0.6×	53 0.3×	31 0.2×	22	484
Zach Liu United States	10	225 0.6×	263 0.8×	125 0.6×	27 0.2×	37 0.3×	12	445
Daniele Bertoloni Italy	9	160 0.4×	304 0.9×	105 0.5×	28 0.2×	35 0.3×	14	432
Jean‐Marc Schiano de Colella France	13	261 0.7×	263 0.8×	33 0.2×	57 0.3×	134 1.0×	41	600
Xi-Wen Bi China	12	397 1.1×	354 1.1×	52 0.3×	25 0.1×	70 0.5×	24	577
Magdalena Adde Sweden	5	385 1.0×	502 1.6×	53 0.3×	15 0.1×	186 1.4×	6	630
Jordan A. Herst Canada	7	201 0.5×	263 0.8×	54 0.3×	21 0.1×	40 0.3×	12	401
Peter Forsyth United Kingdom	7	103 0.3×	152 0.5×	50 0.2×	42 0.2×	35 0.3×	14	391

Countries citing papers authored by John C. Phares

Since Specialization

Citations

This map shows the geographic impact of John C. Phares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Phares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Phares more than expected).

Fields of papers citing papers by John C. Phares

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Phares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Phares. The network helps show where John C. Phares may publish in the future.

Co-authorship network of co-authors of John C. Phares

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Phares. A scholar is included among the top collaborators of John C. Phares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Phares. John C. Phares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Ihde, Daniel C., James L. Mulshine, B S Kramer, et al.. (1994). Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.. Journal of Clinical Oncology. 12(10). 2022–2034. 194 indexed citations

2.

Johnson, Bruce E., Robert Parker, Robert H. Shoemaker, et al.. (1993). Phase I trial of dihydrolenperone in lung cancer patients: A novel compound within vitro activity against lung cancer. Investigational New Drugs. 11(1). 29–37. 6 indexed citations

3.

Johnson, Bruce E., Adi F. Gazdar, May Lesar, et al.. (1993). Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin. Lung Cancer. 9. S21–S26. 19 indexed citations

4.

Longo, Dan L., P L Duffey, Robert C. Young, et al.. (1992). Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.. Journal of Clinical Oncology. 10(2). 210–218. 289 indexed citations

5.

Longo, Dan L., P L Duffey, Vincent T. DeVita, et al.. (1991). Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.. Journal of Clinical Oncology. 9(8). 1409–1420. 42 indexed citations

6.

Medbery, Clinton A., et al.. (1984). Pulmonary blastoma. Case report and literature review of chemotherapy experience. Cancer. 53(11). 2413–2416. 33 indexed citations

7.

Phares, John C.. (1978). Idiopathic Thrombocytopenia Purpura. Archives of Surgery. 113(12). 1480–1480. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact